University of Padua
3 papers in the library · 12 citations · publishing 2021-2024
BMJ November 19, 2024 Cédric Lemarchand, Raphaël Chopin, M Paul et al. 9 citations
The authors identify weaknesses in the evidence regarding the efficacy and safety of hallucinogens and raise concerns about the use of expedited regulatory pathways for these substances.
JAMA Psychiatry April 10, 2024 Eiko I. Fried, Ioana A. Cristea, Florian Naudet 2 citations
A letter to the editor raises three concerns about a published study that tested 25 mg of psilocybin in 15 patients with treatment-resistant type 2 bipolar depression. The authors of the letter identify specific methodological issues with the study protocol but do not present new data or findings.
May 12, 2021 Ioana A. Cristea, Florian Naudet, Clara Miguel 1 citation preprint
A letter to the editor critiques the design and interpretation of a trial comparing psilocybin to escitalopram for depression, arguing that the study's conclusions may be overstated due to methodological issues such as lack of adequate blinding and potential expectancy effects. The author suggests that the reported benefits of psilocybin could be influenced by these factors, and calls for more rigorous research to confirm its efficacy relative to established treatments.